Department of Hepatopancreatobiliary Surgery, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.
Chin Med J (Engl). 2013;126(19):3632-8.
Budd-Chiari syndrome (BCS) is characterized by liver sinusoidal congestion, ischemic liver cell damage, and liver portal hypertension caused by hepatic venous outflow constriction. The aim of this research was to investigate the clinicopathological features of BCS-associated hepatocellular carcinoma (HCC) and explore its surgical treatment and prognosis.
Clinical data from 38 patients with BCS-associated HCC who were surgically treated in our hospital from July 1998 to August 2010 were retrospectively analyzed. The clinicopathological features and prognosis of patients with BCSassociated HCC and surgical treatment for BCS-associated HCC were investigated.
Compared to the patients with hepatitis B virus (HBV)-associated HCC, the patients with BCS-associated HCC showed a female predominance, and had significantly higher cirrhosis rate, higher incidence of solitary tumors, lower incidence of infiltrative growth, higher proportion of marginal or exogenous growth, lower rate of portal vein invasion, and higher degree of differentiation. Median survival was longer in patients with BCS-associated HCC (76 months) than in those with HBV associated HCC (38 months). Of 38 patients with BCS-associated HCC, 22 patients who received combined surgery mainly by liver resection plus cavoatrial shunts exhibited hepatic venous outflow constriction relief, while the other 16 patients only underwent liver resection. The combined surgery group had significantly longer survival and lower incidences of post-operative lethal complications (P < 0.05). Multivariate analysis showed that relief of hepatic venous outflow obstruction was a protective factor for survival of patients with BCS-associated HCC, whereas portal vein invasion was a risk factor.
BCS-associated HCC has a more favorable biological behavior and prognosis than HBV-associated HCC. For patients with BCS-associated HCC, tumor resection accompanied with relief of hepatic venous outflow obstruction can reduce the incidence of complications and extend survival.
布加氏综合征(BCS)的特征是肝窦充血、肝缺血性细胞损伤和肝静脉流出道狭窄引起的门静脉高压。本研究旨在探讨 BCS 相关肝细胞癌(HCC)的临床病理特征,并探讨其手术治疗和预后。
回顾性分析我院 1998 年 7 月至 2010 年 8 月收治的 38 例 BCS 相关 HCC 患者的临床资料。探讨 BCS 相关 HCC 的临床病理特征、手术治疗及预后。
与 HBV 相关 HCC 患者相比,BCS 相关 HCC 患者以女性为主,肝硬化发生率较高,单发肿瘤发生率较高,浸润性生长发生率较低,边缘或外生性生长比例较高,门静脉侵犯率较低,分化程度较高。BCS 相关 HCC 患者的中位生存期(76 个月)长于 HBV 相关 HCC 患者(38 个月)。38 例 BCS 相关 HCC 患者中,22 例行肝切除加腔静脉分流术的联合手术,肝静脉流出道梗阻缓解,另 16 例仅行肝切除术。联合手术组的生存时间明显延长,术后致死性并发症发生率明显降低(P<0.05)。多因素分析显示,肝静脉流出道梗阻的缓解是 BCS 相关 HCC 患者生存的保护因素,而门静脉侵犯是危险因素。
BCS 相关 HCC 的生物学行为和预后优于 HBV 相关 HCC。对于 BCS 相关 HCC 患者,肿瘤切除联合肝静脉流出道梗阻缓解可降低并发症发生率,延长生存时间。